How much revenue does Humanwell Healthcare (Group) make?

Humanwell Healthcare (Group) reported 23.96 billion CNY in revenue for fiscal year 2025, down 5.8% from 25.44 billion CNY in fiscal year 2024. In Q1 2026 revenue was 6.10 billion CNY.

Where does Humanwell Healthcare (Group) make most of its revenue?

China: 86% of revenue by region in fiscal year 2025, followed by Overseas (14%).

What companies are similar to Humanwell Healthcare (Group)?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ), Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ), Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS), Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ).

Humanwell Healthcare (Group) Co.,Ltd. (600079.SS) Stock

About Humanwell Healthcare (Group) Co.,Ltd.

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for pat...

At a glance

Humanwell Healthcare (Group) reported revenue of 23.96 billion CNY for fiscal year 2025, down 5.8% from fiscal year 2024, and net income of 1.86 billion CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 6.10 billion CNY, down 0.6% from a year before. China was its largest region in fiscal year 2025, with 86% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.